Eli Lilly to Sell Rights for its Two Antibiotics and a Manufacturing Facility to Eddingpharm in China for $375M

 Eli Lilly to Sell Rights for its Two Antibiotics and a Manufacturing Facility to Eddingpharm in China for $375M

Eli Lilly to Sell Rights for its Two Antibiotics and a Manufacturing Facility to Eddingpharm in China for $375M

Shots:

  • Eli Lilly to receive $75M upfront & $300M on the completion of transaction. Eddingpharm to get exclusive rights for Lilly’s two antibiotics, Ceclor and Vancocin and a manufacturing facility located in China producing Ceclor. The transaction is expected to close in H2’19/H1’20
  • Additionally, all the employees at the Ceclor’s manufacturing facility will continue to work with Eddingpharm. Lilly will provide ongoing services to Eddingpharm for continuity of product supply & smooth transition of the facility
  • Ceclor & Vancocin are anti-infectives therapies used to treat bacterial infections & penicillin-resistant Staphylococcus aureus respectively. In 2004, Eli Lilly licensed Vancocin to ViroPharma, Flynn Pharma and Aspen Pharmacare in the US, UK and Australia respectively

Click here to read full press release/ article | Ref: Eli Lilly | Image: IndyStar

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post